Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jordan Salibi

Physician Assistant, Surgical Allentown, PA Physician Assistant

NPI 1447628169 CMS profile 10472015

1117 Sherman St, Allentown, PA 18109

Open in the dashboard

General payments

$2,665

57 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jordan Salibi of Allentown, PA is reported in the CMS Open Payments database as having received $2,665 across 57 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $709 22
2024 General $603 13
2023 General $478 6
2022 General $395 7
2021 General $481 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordan Salibi
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Jordan Salibi were reported at $709. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Jordan Salibi Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $481 $111 $36–$285 $132
2022 $395 $126 $44–$350 $149
2023 $478 $137 $47–$355 $160
2024 $603 $146 $49–$384 $164
2025 $709 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Stryker Corporation $1,714 37 payments
  2. Smith+Nephew, Inc. $783 13 payments
  3. Vertex Pharmaceuticals Incorporated $52 3 payments
  4. Zimmer Biomet Holdings, Inc. $40 1 payment
  5. Baxter Healthcare $35 1 payment
  6. DePuy Synthes Sales Inc. $28 1 payment
  7. Pacira Pharmaceuticals Incorporated $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,665 57 payments
Products named General payments · program years 2021–2025
  1. TRIATHLON $657 8 payments
  2. MAKO $588 14 payments
  3. REAL INTELLIGENCE $390 5 payments
  4. INSIGNIA $286 9 payments
  5. CORI $271 6 payments
  6. RESTORATION $258 3 payments
  7. TRIDENT $119 1 payment
  8. TRITANIUM $119 1 payment
  9. REDAPT $112 1 payment
  10. LEGION $93 1 payment
  11. Other $405 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,629

Median for Physician Assistant: 241

Drug cost

$18,718

Median for Physician Assistant: $4,110

Branded share of claims

1.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $7,549
Celecoxib Generic 193 $3,496
Oxycodone Hcl Generic 363 $2,571
Cefadroxil Generic 431 $2,241
Clobetasol Propionate Generic 18 $664
Tizanidine Hcl Generic 92 $617
Methylprednisolone Generic 127 $518
Doxycycline Hyclate Generic 72 $297
Clindamycin Hcl Generic 151 $245
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $166

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$147,739

Of which drugs: $27,731

Medicare patients

659

Average age 74

Services billed

6,853

388 women, 271 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 28%
Chronic kidney disease 18%
COPD 17%
Cancer 17%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 42 3,825 $21,262
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 13 43 $4,201
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 189 1,120 $839

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

57 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record